“…The costs used in this analysis were based on MOH Consumer Price Guide from Pharmaceutical Services Program (2018), Malaysian DRG Casemix costing (severity illness 2), MOH Investigation Charges from website (2018), published literature using local data (Lee WC et al, 2016, Zainal R et al, 2014, Dranitsaris G et al, 2011, Hwa YS et al, 2011 and personal communication with pharmacists from National Cancer Institute, Malaysia. Direct medical costs included were cost of drugs, cost of procedures such as IV and subcutaneous administration of drugs, cost of investigations such as renal profile, cost of SRE related management (pathological fracture, radiotherapy to the bone and spinal cord compression requiring instrumentation), cost of specialist clinic follow-ups and palliative care.…”